- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04703075
Ultra Curto (Ultra Short) TB Prevention Therapy
March 28, 2024 updated by: Johns Hopkins University
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
To compare treatment success (adherence and completion of treatment) and safety of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Tuberculosis (TB) is the leading infectious killer globally and a major cause of illness and suffering.
The World Health Organization has prioritized TB preventive therapy (TPT) for people with latent TB infection (LTBI) as a key strategy for controlling the epidemic.
Prevention of TB with isoniazid preventive therapy (IPT) is effective and reduces morbidity and mortality, and has been the mainstay of TB prevention for decades.
But for an intervention with an excellent evidence of efficacy, global uptake has been abysmal.
Completion rates for IPT when it is administered are poor (Gillespie 2008; Durovni 2010), with a large proportion of patients unable to complete treatment (McClintock 2017; Sterling 2011).
While uptake is influenced by a variety of factors, a critical element has been the duration of IPT, with adherence falling sharply over time in clinical trials and practice.
Shorter course regimens have a much higher completion rate and are more acceptable to patients, clinicians, and programs.
Study Type
Interventional
Enrollment (Actual)
500
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Beatriz Kohler
- Phone Number: 410-614-3812
- Email: bkohler@jhmi.edu
Study Contact Backup
- Name: Richard Chaisson, MD
- Phone Number: 4109551755
- Email: rchaiss@jhmi.edu
Study Locations
-
-
AM
-
Manaus, AM, Brazil, 69040-000
- Fundacao de Medicina Tropical Doutor Heitor
-
-
RJ
-
Rio De Janeiro, RJ, Brazil, 22450-221
- NAPDOT
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 99 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and
- Household contact of an infectious TB case within previous 90 days, defined as sleeping at least once in a residence with a person diagnosed with pulmonary TB, or
- Documented conversion of Tuberculin skin test (TST)/IGRA from negative to positive within 2 years
Exclusion Criteria:
- Documented HIV infection
- Evidence of active tuberculosis on clinical exam or chest x-ray
- Known intolerance of any study drug
- Treatment for active or latent TB in the past for more than 14 days
- Known close contact to someone with INH or rifampin resistant TB
- Active liver disease or Aspartate aminotransferase(AST)/Alanine transaminase (ALT) >3 times upper limit of normal (ULN)
- Neutropenia (ANC <1000)
- Peripheral neuropathy >Grade 1 by DAIDS Grading Table
- Pregnant or breastfeeding. Women of childbearing potential must agree to use non-hormonal contraception during study treatment.
- Weight <40 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rifapentine 600 mg and Isoniazid 300 mg
Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
|
Participants will receive Rifapentine 600 mg and INH 300 mg
|
Active Comparator: Rifapentine 900 mg and Isoniazid 900 mg
Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
|
Participants will receive Rifapentine 900 mg and INH 900mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who complete treatment with >90% adherence
Time Frame: 2 years
|
To compare treatment success (completion of treatment with >90% adherence) of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard Chaisson, MD, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 24, 2022
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
January 7, 2021
First Submitted That Met QC Criteria
January 7, 2021
First Posted (Actual)
January 11, 2021
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifapentine
- Rifampin
Other Study ID Numbers
- IRB00284317
- U01AI152961 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Rifapentine 600 mg and INH 300 mg
-
AbbVieCompletedUlcerative Colitis (UC)United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
-
MedImmune LLCCompletedChronic Obstructive Pulmonary DiseaseUnited States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
-
NeuroBo Pharmaceuticals Inc.CompletedHypercholesterolemia | Hypertriglyceridemia
-
Janssen Research & Development, LLCCompleted
-
AstraZenecaCompletedParkinson's DiseaseUnited States
-
Janssen Research & Development, LLCCompleted
-
Altavant Sciences GmbHParexel; Altavant Sciences, Inc.Completed
-
Khon Kaen UniversityGovernment Pharmaceutical OrganizationCompleted
-
Janssen Infectious Diseases BVBACompleted